Pulmonary lymphangioleiomyomatosis and renal angiomyolipoma in a patient with systemic lupus erythematosus: A case report

Medicine (Baltimore). 2022 Sep 23;101(38):e30554. doi: 10.1097/MD.0000000000030554.

Abstract

Background: The co-incidence of systemic lupus erythematosus (SLE) and tuberous sclerosis with pulmonary lymphangioleiomyomatosis (LAM) and renal angiomyolipoma (AML) is rare. In such patients, the rupture of renal AML may result in fatal circumstances, but this may be preventable.

Methods: A 22-year-old Asian woman with SLE was admitted to our hospital with severe left-flank pain. Imaging studies showed the bilateral rupture of multiple renal AMLs.

Results: The patient underwent emergency selective transcatheter embolization (TE) of the left renal artery. After TE and massive hydration, the patient complained of dyspnea and postembolization syndrome with fever. The chest computed tomography (CT) revealed pulmonary LAM, pulmonary edema with bilateral pleural effusions, and pneumonic consolidation. After the emergency procedure, the patient was treated with intravenous administration of antibiotics, diuretics, and nonsteroidal anti-inflammatory drugs for 10 days. The patient recovered favorably and was discharged 20 days after the treatment. She was diagnosed with renal AML and pulmonary LAM along with facial angiofibromas as well as tuberous sclerosis complex (TSC), although she had no TSC1 or TSC2 gene mutations.

Conclusion: Although rare, SLE may coexist with TSC, along with LAM and AML, with a risk of AML rupture. The activation of the mTOR signaling pathway is shared between SLE and TSC. Thus, in patients with SLE, clinicians should consider imaging studies, such as kidney sonography and chest CT, to screen for possible manifestation of AML and LAM.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angiomyolipoma* / complications
  • Angiomyolipoma* / therapy
  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Bronchial Neoplasms* / complications
  • Diuretics
  • Female
  • Humans
  • Kidney Neoplasms* / complications
  • Kidney Neoplasms* / therapy
  • Lupus Erythematosus, Systemic* / complications
  • Lymphangioleiomyomatosis* / complications
  • Neoplasms, Connective Tissue* / complications
  • TOR Serine-Threonine Kinases
  • Tracheal Neoplasms* / complications
  • Tuberous Sclerosis* / complications
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Anti-Inflammatory Agents
  • Diuretics
  • TOR Serine-Threonine Kinases